Julie Nonnekens

Rotterdam, ZH 3015CN, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.

Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.

Journal: Frontiers in oncology

Published: May 13, 2026

Radiobiological comparison of holmium-166 and yttrium-90 for hepatocellular carcinoma treatment in vitro.

Radiobiological comparison of holmium-166 and yttrium-90 for hepatocellular carcinoma treatment in vitro.

Journal: Nuclear medicine communications

Published: February 26, 2026

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 06, 2026

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

Journal: EJNMMI research

Published: August 06, 2025

3SD: Rotational symmetry single-shot denoising in fluorescence microscopy.

3SD: Rotational symmetry single-shot denoising in fluorescence microscopy.

Journal: Journal of microscopy

Published: July 25, 2025

Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.

Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.

Journal: Cancer medicine

Published: June 10, 2025

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 09, 2025

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells.

Journal: Cancers

Published: June 02, 2025

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy.

Recommendations for reporting preclinical radiobiological studies in targeted radionuclide therapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 24, 2025

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors.

Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: January 07, 2025

Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.

Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 02, 2024

Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response.

Evaluating the Immune Response After Targeted Radionuclide Therapy: Toward a Correlation Between Absorbed Dose and Response.

Journal: International journal of radiation oncology, biology, physics

Published: October 01, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026